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Kevin Crowley is currently a senior at Coastal Carolina University majoring in biochemistry. He 
is scheduled to graduate in May of2012. He has always been strong in the fields of biology and 
chemistry, and he hopes to pursue a career in the field of biochemistry and bioinforrnatics. 
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Since childhood, he has been fascinated with science. He is driven to investigate the numerous 
unknown or poorly understood biological processes of the human body. Some people say coffee 
gets them up in the morning, but Kevin is awoken each day by the unanswered questions in 
science. 
ABSTRACT 
Carnosine is a dipeptide compound that is found in many dietary supplements and food products. 
Carnosine has many functions in the body, such as alleviating oxidative stress on tissues by 
acting as an antioxidant compound. Carnosine, therefore, has important anti-aging properties. 
Carnosine is also capable of forming protective sequestration structures around heavy metal 
ions; this process of chelating metals ions in solutions is very beneficial for maintaining the well-
being of cells in the body. Thus, carnosine could be usefol in pharmaceutical products for 
creating anti-aging drugs that would reduce tissue stress and promote a healthy cellular 
environment. I attempted to co-crystallize carnosine with four polycarboxylated aromatic acids 
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and two Krebs cycle metabolites to generate various supramolecular structures based on the 
placement of carboxyl groups on the co-crystallants. If a co-crystallization method is created for 
carnosine, pharmaceutical products can utilize the same method in producing carnosine-based 
drugs. Furthermore, carnosine chelation of various metal ions was conducted to determine if 
carnosine would chelate in a variety of solution environments. Co-crystallization of carnosine 
with the four polycarboxylated aromatic acids and two Krebs cycle metabolites was not fully 
achieved, possibly due to environmental and stability conditions of solutions. Carnosine 
demonstrated metal-ion chelation properties with copper ions, whereas iron and zinc and iron 
ion solutions did not reveal carnosine chelation properties. In conclusion, more experiments with 
carnosine should be conducted to find optimal co-crystallization conditions for the production of 
pharmaceutical products. 
1.0 Introduction 
Carnosine has many functions in the body, including alleviating oxidative stress and chelating 
metals ions in solutions. Thus, carnosine could be useful in pharmaceutical products. I attempted 
to co-crystallize carnosine with four polycarboxylated aromatic acids and two Krebs cycle 
metabolites to generate various supramolecular structures based on the different placement of 
carboxyl groups on the co-crystallants. Co-crystallization of carnosine with the four 
polycarboxylated aromatic acids and two Krebs cycle metabolites was not fully achieved, 
possibly due to environmental and stability conditions of solutions. Carnosine demonstrated 
metal-ion chelation properties with copper ions, whereas iron and zinc and iron ion solutions did 
not reveal carnosine chelation properties. 
Carnosine is a dipeptide molecule that is synthesized from histidine and alanine (Reeve et a!., 
1993). Also known as p-alanylhistidine, carnosine is a hydrophilic compound that prevents 
oxidative stress in a variety of important biomolecules, tissues, and organisms (Boldyrev et a!. 
2004). Carnosine occurs naturally in high concentrations in active and excitable tissues such as 
heart, brain, and skeletal muscle (Boldyrev et a!. 2004). Many experiments have been conducted 
to observe the effects of carnosine on vertebrates (Janessen eta!. 2005; Brownrigg eta!. 2010; 
Ma et a!. 20 I 0). 
Carnosine inactivates harmful compounds related to oxidative stress and activation of excitatory 
compounds; hydrolysis of carnosine into P-alanine and histidine leads to the production of 
histamine, which is a common neurotransmitter (Suer et a!. 2011 ). Furthermore, carnosine 
inhibits activity of serotonin-derived melanoid, a compound that decreases neurological activity 
and may advance Alzheimer's disease (Brownrigg eta!. 2010). Moreover, carnosine prevents 
diabetic neuropathy, a common condition among diabetics usually resulting in kidney failure and 
even death, by reducing glycosylation and glucose levels in the extracellular matrices of cells 
(Janssen eta!. 2005). When carnosine levels are too high in certain tissues, carnosinase enzymes 
convert carnosine into P-alanine and histidine; both of these amino acids can be used for protein 
synthesis or metabolism (Bertinaria et a!. 2011). Production of carnosinase from the CNDPl 
gene decreases carnosine levels, which can lead to accelerated development of diabetic 
neuropathy (Riedl et a!. 2007). When concentrations of heavy metals, such as copper, cobalt, 
zinc, and iron, are elevated under normal physiological conditions, carnosine creates chelation 
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complexes to isolate and sequester harmful heavy metal ions and prevents them from interacting 
with important biomolecules (Lanza eta!. 2011). Carnosine performs a wide array of protective 
and anti-aging functions that are essential to biological processes throughout the body. Practical 
applications of carnosine have been studied in the meat-processing industry by including 
carnosine in the diet of livestock to preserve meat and prevent spoilage (Ma eta!. 2010). Thus, it 
would be beneficial to use carnosine for medicinal needs and pharmaceutical products based on 
its physical and chemical properties. 
Crystallization is a very common method for precipitating compounds out of solution and tightly 
packing molecules into a stable, solid state. However, not all molecules crystallize easily. 
Therefore, compounds called co-crystallants are used to form crystals in solution; this process is 
used frequently by pharmaceutical companies to condense compounds into pill form. Co-
crystallants are specifically engineered based on the chemical properties and functional groups of 
the molecule that needs to be crystallized. For example, molecules that have many carbonyl, 
hydroxyl, or even nitrogen-bearing functional groups readily form dimers with co-crystallants 
capable of hydrogen bonding (Mahapatra eta!. 2010). Co-crystallants must be fairly stable as to 
not undergo chemical reactions with other compounds in solution; aromatic compounds can be 
used to increase stability of crystallization bonds as well as increase molecular interactions with 
pi-pi stacking of aromatic rings (Qiao et a!. 2011). Aromatic compounds capable of hydrogen 
bonding are likely to co-crystallize with carnosine because of the nitrogen-based and oxygen-
based functional groups present in the molecular structure. Compounds that function as 
important metabolites can also be used successfully for co-crystallization and possible drug 
development due to their harmless nature. For example, compounds such as citrate and a-
ketoglutarate can be used for co-crystallization due to the presence of multiple carboxylic acid 
groups on those compounds. Citrate and a-ketoglutarate are important metabolites in the Krebs 
cycle and contain multiple carboxylic acid groups; thus co-crystallization could be established by 
utilizing these metabolites (Karki et a!. 2007). Using Krebs cycle metabolites and aromatic 
polycarboxylated acids as co-crystallizing agents would be suitable for drug development. 
Carboxylic acids and other carbonyl-based molecules readily form hydrogen bonds and dimers in 
aqueous solutions. By using stable molecules with multiple carboxylic acid groups, such as 
aromatic polycarboxylated acids and Krebs cycle metabolites, co-crystallization of carnosine 
may be achieved through hydrogen bonding, dimer formation, and even pi-pi stacking (Santra 
and Biradha 2009). Various supramolecular structures can be generated by using co-crystallants 
with different placements of key functional groups needed for co-crystallization; polymorphism 
as well as co-crystallization can be achieved (Goswami et a!. 2008). For instance, when 
performing co-crystallization with phthalic acid, crystal structures have been documented to 
resemble long, repeating helices with pi-pi stacking of aromatic rings (Ban et a!. 2009). Crystal 
structures can vary greatly among co-crystallants leading to the formation of numerous types of 
crystals. For example, co-crystallization with compounds containing ortho-carboxylic groups, 
such as those on phthalic acid, can generate several different supramolecular structures based on 
the complexity of molecular interactions during crystallization (Baca eta!. 2006). 
After crystal formation, crystals must be extracted and purified by using simple laboratory 
techniques based on molecular properties. Three-dimensional crystal structures are determined 
via x-ray diffraction, IR spectroscopy, and/or Nuclear Magnetic Resonance (NMR) spectroscopy 
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(Wang et a!. 2009). The purpose of this research project is to successfully co-crystallize 
carnosine with aromatic polycarboxylated acids and examine polymorphism of crystal structures. 
We hypothesized that co-crystallization of carnosine can be achieved by using various aromatic 
polycarboxylated acids and Krebs cycle metabolites that produce different crystal structures 
based on the placement of functional groups on the co-crystallants. We will test four aromatic 
polycarboxylated compounds: isophthalic acid, phthalic acid, terephthalic acid, and trimesic acid. 
Each of these compounds contains two or more carboxylic acid groups bound to a phenyl ring, 
but each compound differs based on the placement of the carboxylic acid groups. Furthermore, 
two important Krebs cycle metabolites, citrate and a-ketoglutarate, will be used to generate 
additional crystal structures based on their incorporation in numerous metabolic pathways that 
can be utilized for possible drug development. To ensure accuracy of results, several trials will 
be conducted for each co-crystallant with carnosine. 
Previous experiments that have been conducted with these polycarboxylated molecules have 
demonstrated a variety of binding properties unique to each compound. For example, trimesic 
acid has been shown to create large complicated supramolecular complexes when metal ions are 
introduced in solution (Chatterjee et al. 2000). Trimesic acid contains three carboxylic acid 
groups, which is more than the number found in other polycarboxylated compounds such as 
terephthalic acid. It has been observed that trimesic acid exhibits weak intermolecular bonding 
due to steric hindrance (Fleischman et a!. 2003). Bonding properties of each of the co-
crystallants will be unique and therefore produce different crystal structures. 
Practical applications of this experiment are possible based on the ion-chelating properties of 
carnosine. Under conditions where harmful, free iron ions were present, carnosine could prevent 
iron ions from causing oxidative stress and disrupting cellular activity. Red blood cell disorders 
that cause denatured hemoglobin to release iron ions into the bloodstream are problematic due to 
the oxidative properties of free iron ions. Excess amounts of iron can be removed from the body 
with iron-chelation therapy (Porter 2009). Carnosine has shown chelating properties when 
exposed to oxidizing copper ions (Decker et al. 2000). However, carnosine has not yet been 
observed to form iron-chelation complexes (Morrissey et al. 1998). Therefore, one objective for 
this experiment is to achieve iron chelation of carnosine under a variety of different conditions. 
By coupling the conditions at which iron chelation of carnosine occurs and crystal structures 
generated from carnosine co-crystallization, it may eventually be possible to develop a 
carnosine-based drug to chelate excess iron ions in the bloodstream. 
2.0 Materials and Methods 
2.1 Stock Solutions 
Each of the six co-crystallant solutions and the carnosine solution were created in mass quantities 
to easily replicate crystallization trials. Optimal crystallization conditions for small molecules 
occurs around 0.1 M of each solution. Stock solutions were composed of I 00 mL deionized water 
with 0.1 moles of solute; O.IM (I 0 mmol/1 00 mL solution) solutions of carnosine, phthalic acid, 
isophthalic acid, terephthalic acid, trimesic acid, citrate, and a- ketoglutarate were created as 
stock solutions. Carnosine powder and O.IM carnosine were stored under refrigeration because 
carnosine degrades at room temperature. The other co-crystallant solutions and corresponding 
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powder samples were kept at room temperature. The polycarboxylated aromatic acids (phthalic 
acid, isophthalic acid, terephthalic acid, and trimesic acid) are partially insoluble in water; 
therefore additional solvents such as ethanol, acids, and bases were added to the solutions to 
create homogenous mixtures. 
2.2 Co-crystallization at Room Temperature 
Glassware used in the experiment consisted primarily of25 mL, sealed, round-bottom flasks and 
class-A 10 mL pipets to ensure accuracy and precision of results. Ten mL of O.IM carnosine 
solution were mixed with I 0 mL of O.IM phthalic acid in a flask and left at room temperature for 
slow-evaporation crystallization to occur. This procedure was repeated for isophthalic acid, 
terephthalic acid, trimesic acid, citrate, and a-ketoglutarate solutions in separate flasks. The 
procedure was repeated for each co-crystallant in unsealed, open-top flasks, thus allowing faster 
evaporation at room temperature, which could possible produce crystals at a faster rate or 
produce different types of crystals. 
2.3 Carnosine Chelation with Metal Ions 
Chelation properties of carnosine were tested by using iron, copper, and zinc ions in solution. 
Optimal chelation conditions were obtained by using O.!M solutions of both carnosine and metal 
ion solutions. Stock solutions were created at O.!M of iron (Fe3+ from Fe(N03)3), copper (Cu2+ 
from Cu(N03)2), and zinc (Zn2+ from Zn(N03)2). Ten mL ofO.IM carnosine were mixed with 10 
mL of O.IM metal ion solution in 25 mL, sealed, round-bottom flasks and kept at room 
temperature. The process was repeated for each metal ion solution using 25 mL, open-top flasks. 
2.4 Co-Crystallization and Chelation with Metal Ions 
Stock solutions were created at O.IM with iron (Fe3+ from Fe(N03)3), copper (Cu2+ from 
Cu(N03)2), and zinc (Zn2+ from Zn(N03)2) with the addition of I 0 mL of 0.1 M a-ketoglutarate 
to each solution as a co-crystallizing agent. Equal volumes of O.IM metal ion solution and a-
ketoglutarate solution were added to 0.1 M carnosine in 25 mL, sealed, round-bottom flasks and 
kept at room temperature. This process was repeated with citrate; a total of six O.IM metal ion 
stock solutions with co-crystallants were made. 
2.5 Analysis of Crystal Structures 
After crystals-like structures were achieved in solution, crystals would then be observed via x-
ray diffraction to determine the three-dimensional crystal lattices created from co-crystallization. 
The materials needed for x-ray diffraction were not present at Coastal Carolina University; 
therefore crystals would be sent to Dr. Frank Fronzcek at Louisiana State University Department 
of Chemistry (an associate of Dr. Evans). NMR spectroscopy was used to further analyze crystal 
structures in order to corroborate the data from x-ray diffraction. Metal ion solutions were 
analyzed by using UV-Vis spectroscopy in the Smith Science Center at Coastal Carolina 
University. Solutions containing pure metal ions were run as blanks in the UV-Vis spectroscopy; 
differences in absorbance peaks between the blanks and carnosine solutions would be indicative 
of chelation or alternative-bonding structures, as opposed to two free molecular species in 
Bridges, No. 6, Spring 2012 
23 
solution. The results were compiled and analyzed to generate supramolecular bonding models for 
carnosine. 
3. Results 
Stock solutions were made successfully for five of seven compounds. Carnosine, citrate, and a-
ketoglutarate readily dissolved in solution without the need for additional solvents. Phthalic acid, 
isophthalic acid, terephthalic acid, and trimesic acid were mostly insoluble in water and did not 
dissolve initially. Carbonic acid was added to each of the four polycarboxylated aromatic acid 
solutions in increments of I 0 mL to observe changes in solubility. A total of 50 mL of carbonic 
acid was added to each of the four solutions, which yielded no change in solubility; undissolved 
solids remained. New solutions were created by adding 0.01 mole of each polycarboxylated 
aromatic acid to 100 mL of ethanol to create O.JM solutions. Ethanol-based solutions oftrimesic 
acid and phthalic acid were created successfully, whereas terephthalic acid and isophthalic acid 
remained largely insoluble. Stronger base solutions were used in an attempt to dissolve 
isophthalic acid and terephthalic acid; 6M NaOH successfully dissolved isophthalic acid, but not 
terephthalic acid. Organic solvents were needed to make terephthalic acid miscible in water. 
Accordingly, 0.01 mole of terephthalic acid successfully dissolved in I 00 mL of pyridine to 
create a stock solution. 
Precipitate and crystals formed at different rates in the co-crystallization solutions; therefore 
crystal solutions were not analyzed until the end of the experiment. In addition, it was unknown 
whether or not structures generated in solution were crystals until extraction and analysis were 
performed. Precipitated and/or crystal structures quickly formed in citrate and a-ketoglutarate 
solutions. It was noted that citrate solutions in both sealed and open-top flasks generated three to 
five large crystal-like structures, whereas a-ketoglutarate solutions generated ten to twelve small 
crystal-like structures. Open-top 0.1M trimesic acid in ethanol with 0.1M carnosine generated 
one massive crystal-like structure stuck to the bottom of the flask with needle-shaped 
projections; five to seven small floating crystals were also formed in solution. All other solutions 
did not contain any precipitate or crystals; only a homogenous mixture was present with no signs 
of solids forming in solution. 
The five O.JM carnosine co-crystallization solutions (O.IM citrate open-top and sealed flasks, 
0.1 M a-ketoglutarate open-top and sealed flasks, and 0.1 M trimesic acid with ethanol) that 
contained precipitate/crystals underwent extraction of solids in solution. It was observed that the 
solids in solution were not actually crystal structures based on their appearance and their inability 
to remain solid at room temperature. NMR was not conducted on any of the solutions due to 
difficulties that arose with the instrument over the course of the semester. 
Data collected from UV-Vis spectroscopy revealed the chelation properties of carnosine with 
different metal ions in solution. There was a shift in the absorbed light spectrum for copper ion 
solutions with 0.1M carnosine (Figure I). The shift in light absorbance is indicative of alternative 
binding species in solution, such as chelation; therefore the results indicated copper-carnosine 
chelation in solution for both sealed and open-top solutions. There were no apparent shifts in 
spectral absorbance in the other eight chelation solutions indicating that no chelation occurred 
(Figures 2- 9). 
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4. Discussion 
Based on the results from the experiment, the hypothesis was not fully supported. Attempted co-
crystallization of carnosine with polycarboxylated aromatic acids and Krebs cycle metabolites 
was mostly unsuccessful. Crystals did not form in the any of the solutions, but there were 
precipitates and crystal-like structures that formed in carnosine co-crystallization solutions 
containing a-ketoglutarate (sealed and open-top), citrate (sealed and open-top), and trimesic acid 
in ethanol (open-top). It was observed that the solids in solution were not actually crystal 
structures based on their appearance and their inability to remain in solid form at room 
temperature. Crystals are condensed, solid, organized structures; the solids extracted from all the 
solutions were somewhat gel-like (Harris 2010). Crystallization in early stages can be regarded 
as a physical gelling process where gel-like structures are generated before actual crystals form 
(Pogodina & Winter 1998). It is possible that the amorphous solids in solution were actually 
early stages of crystals, and would require additional time to crystallize. None of the solutions 
yielded crystals over the course of the semester and there was no apparent co-crystallization that 
occurred. We planned to use NMR spectroscopy to determine if there was co-crystallization 
occurring on a small scale in solution, but the NMR instrument at Coastal Carolina University 
was nonfunctional. 
Citrate and a-ketoglutarate solutions formed precipitate quickly, possibly because both of these 
metabolites and carnosine are hydrophilic and contain many carboxylic acid groups to form 
amorphous solids. Co-crystallization may have occurred, not on the supramolecular level as 
hypothesized, but on a microscopic level, which was unable to be determined with the 
instrumentation at Coastal Carolina University. Furthermore, the inability to co-crystallize 
carnosine with the co-crystallants could have arisen due to environmental conditions and/or 
properties of the stock solutions that were created. It was anticipated that the placement of 
carboxylic acid groups would stabilize polycarboxylated compounds in water and therefore 
create a sufficient environment for co-crystallization. The polycarboxylated aromatic acids were 
not fully soluble in water and the addition of strong bases and organic solvents was needed to 
create stock solutions. Inability to attain water-based solutions could have affected the co-
crystallization process due to the fact that carnosine is hydrophilic and does not react well with 
organic solvents and strong bases. Additionally, crystallization is a slow process and requires 
stable environmental conditions (Dale et a!. 2003). Co-crystallization may have been successful 
in a refrigerated or climate-controlled environment to assure more stable conditions. 
Based on data collected from UV-Vis spectroscopy, only copper-ion solutions exhibited 
carnosine chelation, whereas the other eight solutions did not. Carnosine has been known to 
chelate with copper ions and in some scenarios with iron and zinc (Trombley et a!. 1999; Porter 
2009). The data from the eight solutions that did not experience chelation show slight peak shifts 
in spectral data that could be misinterpreted as chelation (Figures 2 - 9). Figures 2, 4 and 8 have 
spectral peak shifts that seem indicative of chelation because they exhibit slight shifts in light 
absorbance. Moreover, chelation can be detected via NMR and chelation-ion chromatography 
(Huang et a!. 2002). Therefore, using UV-Vis spectroscopy may not have been the best choice 
for testing chelation properties of carnosine in metal ion solutions; additional instrumentation, 
such as NMR and chelation-ion chromatography, could be used in future experiments to further 
test and record chelation results from this experiment. 
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To improve the methods for future experiments, co-crystallization of carnosine should be 
conducted under more stable environmental conditions and possibly at colder temperatures to 
ensure slow crystallization, rather than quick precipitation and formation of amorphous solids. 
Additionally, optimal solubility conditions should be identified for carnosine and the 
polycarboxylated aromatic acid co-crystallants; the crystallization process should occur easily if 
both solutes are stable and not precipitating in solution. Crystallization is a slow process that 
requires adequate time for slow formation of crystals in solution (Young et a!. 1999). Thus, the 
time span over which the experiment occurred could be lengthened in order to form crystals that 
are suitable for x-ray diffraction. Finally, chelation properties of carnosine could be tested using 
NMR spectroscopy to corroborate data collected from UV-Vis spectroscopy. 
In conclusion, carnosine co-crystallization with polycarboxylated aromatic acids and Krebs cycle 
metabolites was not achieved, possibly due to conditions of the environment and of the aqueous 
solutions. Furthermore, chelation of metal ions with carnosine was not achieved, with the 
exception of copper. Improvements such as changing environmental conditions, allotting more 
time, and using more up-to-date instrumentation could lead to future success with this 
experiment. 
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Figure !--Spectral analysis of copper and carnosine chelation in sealed and open-top 
solutions. X-axis is wavelength of light in nanometers (nm) and theY-axis is absorbance 
of light (arbitrary absorbance units). The arrows pointing to peak shifts in absorbance 
indicate copper ion chelation with carnosine. 
RETURN TO TEXT 
Bridges, No.6, Spring 2012 
27 
3.00000 
2.00000 Fe3+ Chelation Carnosine 
-=O.lM Fe3+ (Blank) 
-=O.lM Fe3.;. and O.lM Carnosine (Sealed) 
-=0.1M Fe3+ and O.lM Carnosine {Open-Top} 
1.00000 
-1.00000~~~~~~~~~~~~~~~~~~~~~~~~~~ 
300.0000 400.0000 600.0000 800.0000 900.0000 
nm. 
Figure 2--Spectral analysis of iron and carnosine chelation in sealed and open-top 
solutions. X-axis is wavelength of light in nanometers (nm) and theY-axis is absorbance 
of light (arbitrary absorbance units). There are no peak shifts in absorbance values 
between both solutions, which indicate no iron chelation with carnosine. 
RETURN TO TEXT 
Bridges, No.6, Spring 2012 
28 
' 
1.000001-- Zn2.;.Chelation Carnosine -
-=O.lM Zn2+ (Blank) 
-=O.lM Zn2.;. and O.lM Carnosine (Sealed) 
8\ -=O.lM Zn2+ and O.lM Carnosine (Open-Top) 
~ ~------------------~; 
0.00000~~""'="!===============~~ 
-1 .00000 '-'--'-~_j_~~~~~~~'---'--'--'---'~-'-~~--'-~~-'--' 
300.0000 400.0000 600.0000 800.0000 900.0000 
nm. 
Figure 3 Spectral analysis of zinc and carnosine chelation in sealed and open-top 
solutions. X-axis is wavelength of light in nanometers (nm) and theY-axis is absorbance 
of light (arbitrary absorbance units). There are no peak shifts in absorbance values 
between both solutions, which indicate no zinc chelation with carnosine. 
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Figure 4--Spectral analysis of copper, a-ketoglutarate, and carnosine chelation in sealed 
and open-top solutions. X-axis is wavelength of light in nanometers (nm) and theY-axis 
is absorbance of light (arbitrary absorbance units). There are no peak shifts in absorbance 
values between both solutions, which indicate no copper chelation with a-ketoglutarate 
and or carnosine. 
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Figure 5: Spectral analysis of copper, citrate, and carnosine chelation in sealed and open-
top solutions. X-axis is wavelength of light in nanometers (nm) and theY-axis is 
absorbance of light (arbitrary absorbance units). There are no peak shifts in absorbance 
values between both solutions, which indicate no copper chelation with citrate and/or 
carsonine. 
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Figure 6: Spectral analysis of iron, a-ketoglutarate, and carnosine chelation in sealed and 
open-top solutions. X-axis is wavelength oflight in nanometers (nm) and theY-axis is 
absorbance of light (arbitrary absorbance units). There are no peak shifts in absorbance 
values between both solutions, which indicate no iron chelation with a-ketoglutarate 
and/or carnosine. 
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Figure 7: Spectral analysis of iron, citrate, and carnosine chelation in sealed and open-
top solutions. X-axis is wavelength oflight in nanometers (nm) and theY-axis is 
absorbance of light (arbitrary absorbance units). There are no peak shifts in absorbance 
values between both solutions, which indicate no iron chelation with citrate and/or 
carnosine. 
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Figure 8: Spectral analysis of zinc, a-ketoglutarate, and carnosine chelation in sealed and 
open-top solutions. X-axis is wavelength of light in nanometers (nm) and the Y -axis is 
absorbance of light (arbitrary absorbance units). There are no peak shifts in absorbance 
values between both solutions, which indicate no zinc chelation with a-ketoglutarate 
and/or carnosine. 
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Figure 9: Spectral analysis of zinc, citrate, and carnosine chelation in sealed and open-
top solutions. X-axis is wavelength oflight in nanometers (nm) and theY-axis is 
absorbance of light (arbitrary absorbance units). There are no peak shifts in absorbance 
values between both solutions, which indicate no zinc chelation with citrate and/or 
carnosine. 
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